Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/315743

Lähdeviite

Paajanen , J , Ilonen , I , Lauri , H , Järvinen , T , Sutinen , E , Ollila , H , Rouvinen , E , Lemström , K , Räsänen , J , Ritvos , O , Koli , K & Myllärniemi , M 2020 , ' Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy ' , Clinical Lung Cancer , vol. 21 , no. 3 , pp. E142-E150 . https://doi.org/10.1016/j.cllc.2019.10.013

Julkaisun nimi: Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy
Tekijä: Paajanen, Juuso; Ilonen, Ilkka; Lauri, Helena; Järvinen, Tommi; Sutinen, Eva; Ollila, Hely; Rouvinen, Eeva; Lemström, Karl; Räsänen, Jari; Ritvos, Olli; Koli, Katri; Myllärniemi, Marjukka
Tekijän organisaatio: Keuhkosairauksien yksikkö
Helsinki University Hospital Area
INDIVIDRUG - Individualized Drug Therapy
Research Programs Unit
Faculty of Medicine
HUS Heart and Lung Center
Department of Surgery
Clinicum
III kirurgian klinikka
Department of Diagnostics and Therapeutics
University of Helsinki
Sydän ja rintaelinkirurgia
Department of Medicine
Department of Pathology
TRIMM - Translational Immunology Research Program
HUSLAB
Department of Physiology
Growth factor physiology
Katri Koli / Principal Investigator
Päiväys: 2020-05
Kieli: eng
Sivumäärä: 9
Kuuluu julkaisusarjaan: Clinical Lung Cancer
ISSN: 1525-7304
DOI-tunniste: https://doi.org/10.1016/j.cllc.2019.10.013
URI: http://hdl.handle.net/10138/315743
Tiivistelmä: Activin A has previously been associated with cancer cachexia and in vitro resistance to platinum-based chemotherapy. We studied circulating activin A concentrations as well as activin B and their antagonists' follistatin/follistatin-like 3 in presurgical patients with non-small-cell lung cancer and malignant pleural mesothelioma. We found that circulating activing A levels were elevated in malignant pleural mesothelioma and associated with cancer cachexia and poor response to platinum-based chemotherapy. Circulating activing A separated non-small-cell lung cancer from benign lung lesion. Background: Previous preclinical studies have shown that activin A is overexpressed in malignant pleural mesothelioma (MPM), associates with cancer cachexia, and is observed in in vitro resistance to platinum-based chemotherapy. We evaluated circulating activin levels and their endogenous antagonists' follistatin/follistatin-like 3 in intrathoracic tumors. Materials and Methods: Patients suspected of thoracic malignancy were recruited prior to surgery. Serum samples were collected from 21 patients with MPM, 59 patients with non-small-cell lung cancer (NSCLC), and 22 patients with benign lung lesions. Circulating activin/follistatin levels were measured using enzymelinked immunosorbent assay and compared with clinicopathologic parameters. Results: Circulating activin A levels were elevated in patients with MPM when compared with patients with NSCLC or benign lung lesion samples (P <.0001). Also, follistatin and follistatin-like 3 levels were the highest in MPM, although with less difference compared with activin A. Receiver operating characteristic analysis for activin A for separating NSCLC from benign lung lesion showed an area under the curve of 0.856 (95% confidence interval, 0.77-0.94). Activin A levels were higher in patients with cachexia (P <.001). In patients with MPM, activin A levels correlated positively with computed tomographybased baseline tumor size (R = 0.549; P = .010) and the change in tumor size after chemotherapy (R = 0.743; P = .0006). Patients with partial response or stable disease had lower circulating activin A levels than the ones with progressive disease (P = .028). Conclusion: Activin A serum level could be used as a biomarker in differentiating malignant and benign lung tumors. Circulating activin A levels were elevated in MPM and associates with cancer cachexia and reduced chemotherapy response. (C) 2019 The Author(s). Published by Elsevier Inc.
Avainsanat: 3122 Cancers
Mesothelioma
NSCLC
Biomarker
Activin A
Cancer cachexia
Chemotherapy response
SOLID TUMORS
SARCOPENIA
PROGNOSTIC VALUE
BIOMARKERS
SERUM CONCENTRATIONS
CISPLATIN
GROWTH
MYOSTATIN
FOLLISTATIN
EXPRESSION
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by_nc_nd
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: acceptedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
1_s2.0_S1525730419302876_main.pdf 1.095MB PDF Avaa tiedosto
PIIS1525730419302876.pdf 367.0KB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot